UBS AM’s Enzo Biochem, Inc. ENZ Stock Holding History

UBS AM’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-142	Closed	-$585	–	2829
2018 Q3	$585	Sell	142 -213	-60%	-$968	﹤0.01%	2761
2018 Q2	$1.84K	Hold	355	–	–	﹤0.01%	2752
2018 Q1	$1.95K	Hold	355	–	–	﹤0.01%	2631
2017 Q4	$2.89K	Hold	355	–	–	﹤0.01%	2544
2017 Q3	$3.72K	Sell	355 -1	-0.3%	-$11	﹤0.01%	2491
2017 Q2	$3.93K	Hold	356	–	–	﹤0.01%	2472
2017 Q1	$2.98K	Hold	356	–	–	﹤0.01%	2427
2016 Q4	$2K	Buy	+356	New	+$2.27K	﹤0.01%	2454
2016 Q3	–	Sell	-81,731	Closed	-$488K	–	2607
2016 Q2	$488K	Sell	81,731 -458,136	-85%	-$2.54M	﹤0.01%	1965
2016 Q1	$2.46M	Sell	539,867 -126,524	-19%	-$563K	﹤0.01%	1288
2015 Q4	$3M	Buy	666,391 +3,540	+0.5%	+$14.9K	﹤0.01%	1254
2015 Q3	$2.1M	Sell	662,851 -7,919	-1%	-$24K	﹤0.01%	1401
2015 Q2	$2.03M	Buy	670,770 +299,278	+81%	+$841K	﹤0.01%	1399
2015 Q1	$1.1M	Buy	+371,492	New	+$1.22M	﹤0.01%	1593

Other funds holding ENZ

EGA

Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RAM

Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM's ENZ Position: Q4 2018 in Review

UBS AM sold out of Enzo Biochem, Inc. (ENZ) in Q4 2018, closing a stake of 142 shares — an estimated $585 sold.

UBS AM first reported a position in ENZ in Q1 2015 and held it in 14 quarters. The position peaked at $3M in Q4 2015. 91 funds tracked by Wall St. Rank hold ENZ as of Q4 2018.

UBS AM reported no remaining Enzo Biochem, Inc. position as of Q4 2018 after selling out during the quarter.
UBS AM sold 142 Enzo Biochem, Inc. shares in Q4 2018, an estimated $585.
UBS AM first reported a position in Enzo Biochem, Inc. in Q1 2015 and held it in 14 quarters.
UBS AM's Enzo Biochem, Inc. position peaked at $3M in Q4 2015.
91 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q4 2018.

Based on UBS AM's 13F filing for Q4 2018, filed 13 Feb 2019.